Theravance Biopharma (TBPH) Other Non-Current Assets (2013 - 2026)

Theravance Biopharma (TBPH) has reported Other Non-Current Assets for 13 consecutive years, with $836000.0 the latest figure, recorded in Q1 2026.

• In Q1 2026, Other Non-Current Assets changed 0.0% year-over-year to $836000.0; the TTM figure through Mar 2026 stood at $836000.0 (changed 0.0% YoY), while the FY2025 annual figure was $24.9 million, up 102.51% from the prior year.
• Other Non-Current Assets slipped to $836000.0 in Q1 2026 per TBPH's latest filing, from $24.9 million in the prior quarter.
• Across five years, Other Non-Current Assets topped out at $24.9 million in Q4 2025 and bottomed at $836000.0 in Q1 2022.
• Historically, Other Non-Current Assets has averaged $5.5 million across 5 years, with a median of $836000.0 in 2022.
• Annual changes were most pronounced in 2024 — Other Non-Current Assets surged 1369.62% — and 2025, when it plunged 89.41%.
• Theravance Biopharma's Other Non-Current Assets stood at $836000.0 in 2022, then changed by 0.0% to $836000.0 in 2023, then soared by 1369.62% to $12.3 million in 2024, then soared by 102.51% to $24.9 million in 2025, then tumbled by 96.64% to $836000.0 in 2026.
• Business Quant data shows TBPH's Other Non-Current Assets at $836000.0 in Q1 2026, $24.9 million in Q4 2025, and $836000.0 in Q3 2025.